Introducing First Quality Control Test for Therapeutic Tissue Stem Cells

by Asymmetrex on March 14, 2017

On March 8-9 in Boston, stem cell medicine biotechnology start-up Asymmetrex led attendees at the 6th Annual Clinical Trials Supply New England 2017 conference in discussions about the need for quality controls for the supply of tissue stem cells used for treatments in either FDA-approved clinical trials or unregulated private stem cell clinics. Though these two stem cell treatment settings are often contrasted regarding their safety and effectiveness, Asymmetrex stressed that patient care and research progress is compromised in both because of the lack of essential quality control tests for the number and quality of transplanted tissue stem cells.

At the 6th Annual Clinical Trials Supply New England 2017 conference, held in Boston from March 8-9, James Sherley, M.D., Ph.D., director of Asymmetrex, led discussions that evaluated the quality of U.S. supplies of stem cells used in clinical trials compared to private stem cell clinics. Private stem cell clinics have been criticized for not employing research standards that are necessary to establish the therapeutic effectiveness of treatments with statistical confidence. In part because of this difference in practice, they are also often accused of making unproven claims about the effectiveness of their therapies.

Sherley presented comparisons of key operational elements to argue that, given good intent in both settings, the two different settings of stem cell treatments had both distinct and shared shortcomings. He noted, however, that the most significant shortcoming, which stem cell clinical trials and private stem cell clinics share, was perennially overlooked.

Based on the number of reported stem cell clinical trials and private stem cell clinics, Sherley estimated that close to a quarter-million patients in the U.S. now receive stem cell treatments each year. Though many of these occur within FDA-approved clinical trials, their number is dwarfed nearly 10 times by the number of treatments that occur in private stem cell clinics. It shocked the audience of clinical trial suppliers to learn that there was no stem cell quality control test performed for any of these many treatments.

Even for approved stem cell medicine treatments like bone marrow transplantation and umbilical cord blood transplant, there is no stem cell-specific quality control test available. Counts of total cells are made, but these do not adequately predict stem cell number or function. Biomarkers designated for tissue stem cells are also expressed by stem cells’ more abundant non-stem cell products. So, the biomarkers lack sufficient specificity to be used to count and monitor tissue stem cell function.

Without a quality control test for tissue stem cell number, stem cell treatments in all settings proceed without knowing the dose of treating tissue stem cells. This previously unavoidable therapeutic blind spot creates an instant treatment risk. It also precludes effective analyses to optimize treatment procedures, to compare different treatments, or to relate treatment outcomes to tissue stem cell dose. Without knowing stem cell dose, the interpretation of any stem cell treatment in terms of stem cells as the responsible agents is compromised.

In this context, Sherley announced briefly to attendees that Asymmetrex’s new AlphaSTEM Test for counting adult tissue stem cells and providing data on their viability and tissue cell renewal function represented the needed first quality control test for tissue stem cell treatments, whether in clinical trials, in private stem cell clinics, or approved therapies. In particular, he indicated that both stem cell treatment patients and progress in stem cell medicine would benefit from existing clinical trial supply companies developing into future private stem cell clinic supply companies to ensure the quality of stem cell treatment preparations. Sherley said that, of course, their partnership with Asymmetrex to implement its new stem cell-specific quality control test was an all around best solution for accelerating progress in stem cell transplantation medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexIntroducing First Quality Control Test for Therapeutic Tissue Stem Cells

Asymmetrex’s Head Will Lead Discussion on Supplying Private Stem Cell Clinics

by Asymmetrex on March 7, 2017

On March 8-9 in Boston, stem cell medicine biotechnology start-up Asymmetrex will take the lead in introducing a potentially controversial topic to attendees at the 6th Annual Clinical Trials Supply New England 2017 conference. Executives from contract research organizations that supply companies running FDA-approved stem cell clinical trials will be presented with the proposition of promoting advances in stem cell medicine by also supplying private clinics that offer medical treatments with adult tissue stem cells.

Recent scientific reports put the number of private clinics offering stem cell medical treatments in the U.S. at greater than 400. More than 300 of these clinics emerged since 2009. They mirror the rapid increase in FDA-approved clinical trials during the same period at a rate of about 300 new therapy-focused adult tissue stem cell trials each year. However, because of the inherently small number of patients enrolled in early clinical trials and the much larger number of patients seen in medical clinics, the number of stem cell treatments performed in private clinics dwarfs the number in clinical trials by more than 10-fold.

In both settings, treatment cell transplants per se appear generally safe, as long as proper care is given to other routine safety factors, which include mainly keeping treatments free of infectious agents and chemical contaminants and avoiding immune reactions. These safety procedures fall well within the training and expertise of physicians in private clinics, as well as in hospital-based clinical trials.

The rapid growth of private stem cell clinics has alarmed some stem cell scientists and their member organizations. The clinics are accused of making false claims, exploiting patients’ pain and distress for financial gain, and generally harming the reputation of stem cell science. In contrast, in FDA-approved clinical trials, patient volunteers are necessarily informed that their treatments are experimental, and therefore may bring them no medical benefit. Generally, trial subjects do not pay for their treatment, though often treatment costs are covered by their personal health insurance.

Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D., recently began a public discourse, in which he argues that in the important respects private stem cell clinics are not all that different than FDA-approved clinical trials. First, he says that glibly painting all several hundred or more private stem cell clinics as exploitive is an unsubstantiated claim itself. Generally, physicians in both settings are diligently looking for ways to improve the health of patients – clinical trial physicians in the more distant future and private clinic physicians immediately. Sherley, a physician scientist, stresses the importance of recognizing medical empiricism as an important contributor to the advance of modern medicine and medical science.

At the conference, Sherley is scheduled to lead a panel discussion on the topic on March 8 at 15:50 PM (EDT) and give a talk on March 9 at 13:30 PM (EDT). A major new position he will present is that the volume of stem cell treatments now occurring in private clinics is much too large to simply disparage and attempt to shut down. Working to improve the quality of private stem cell clinic treatments for patients and to improve their documentation towards accelerating progress in stem cell medicine is a better goal.

To attendees at this week’s Clinical Trials Supply conference, Sherley will suggest that the supply of private stem cell clinics with high quality, certified sources of stem cells is an underappreciated crucial need for advancing stem cell medicine. The companies that are able to mobilize to fill in this supply gap could have a 10-fold greater impact on advancing stem cell medicine compared to their current minimal impact in FDA-approved stem cell clinical trials.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAsymmetrex’s Head Will Lead Discussion on Supplying Private Stem Cell Clinics

AlphaSTEM Test: Established to Be a Leading Interest for Regenerative Medicine

by Asymmetrex on January 10, 2017
Boston’s stem cell medicine biotechnology start-up Asymmetrex is beginning 2017 with exciting news for its recently launched contract service for counting adult tissue stem cells. The company’s webinar, produced with the international regenerative medicine social media network RegMedNet to describe Asymmetrex’s new counting technology and its applications, was 4th among the 10 most popular content features on RegMedNet for 2016.

Asymmetrex AlphaSTEM Test Adult Tissue Stem Cell Counting Technology Established to Be a Leading Interest for Regenerative Medicine in 2016

At the end of 2015, James Sherley, M.D., Ph.D., founder and director of Asymmetrex, made a decision to enlist RegMedNet as a partner in beginning the targeted introduction of the company’s new technology for counting adult tissue stem cells to stem cell research and stem cell medicine communities internationally. RegMedNet’s focus on accelerating progress in the field of regenerative medicine promised to engage a particularly relevant community of future users of the new technology.

In early 2016, the new partnership produced a series of scientific perspectives that illuminated the long-standing need for a means to count adult tissue stem cells in several varied research and medical disciplines. These included applications needed in stem cell transplantation medicine, regenerative medicine clinical trials, drug development, and general stem cell research. The unique series of perspectives, which highlighted the scientific, medical, and clinical potential precluded for more than half a century by the inability to count tissue stem cells was followed by a webinar describing Asymmetrex’s new solution to the counting problem.

It is gratifying, to say the least, that RegMedNet visitors showed such a high degree of interest in Asymmetrex’s new AlphaSTEM Test for counting adult tissue stem cells. Establishing that such an attraction exists in this particular international forum predicts that Asymmetrex’s new contract service for specific counting and monitoring of stem cells from many different human tissues, launched in September 2016, will continue to build its client base in 2017. The company will continue to partner with RegMedNet for this purpose.

Asymmetrex Director Sherley says that he is putting the RegMedNet partnership among his good decisions for the growth and development of Asymmetrex. However, he adds, “Surely, though, this is only the first indication of the tremendous awareness of what Asymmetrex has accomplished that will follow.”

About Asymmetrex
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAlphaSTEM Test: Established to Be a Leading Interest for Regenerative Medicine

Asymmetrex Director Shares Vision for Company

by Asymmetrex on November 17, 2016
On November 15, James L. Sherley, M.D., Ph.D., Director of stem cell biomedicine technology company Asymmetrex, contributed nearly simultaneously to two related Arena International Events Group forums for clinical trials development. While presenting Asymmetrex’s stem cell medicine business vision at the event group’s 1st Annual Preclinical Development Operations Conference in Boston, a new perspective written by Sherley was published online at the Arena International news site for addressing challenges in clinical trials operations.

Asymmetrex Director Shares Vision for Company and Private Stem Cell Treatment Clinics in Two Arena International Event Group Forums

“Asymmetrex is on the path to success.” James Sherley, director of Asymmetrex, confidently spoke these words when he recounted the business development progress of the company that he founded three years earlier. Sherley was speaking at the 1st Annual Preclinical Development Operations Summit, organized by Arena International Events Group, on November 15-16, in Boston.

Developing more effective collaboration and partnership between contract research organizations (CRO) and their pharmaceutical company and cell therapy company sponsors was the major focus of the Summit. However, in addition to attendance by heads of drug development and cell therapy development from well-established companies, the Summit also included executives from new pharmaceutical and CRO start-ups. Asymmetrex, having recently launched a new contract service that provides, for the first time, tissue stem cell counting for both support of drug development and stem cell therapeutics, was invited to present. Director Sherley reviewed the company’s current business strategy and its longer-term vision of leveraging the new CRO business towards future success as an adult tissue stem cell biomanufacturing company.

Fifteen minutes before Sherley began his presentation on the first day of the Summit, at 12 pm EDT, the clinical trials news site of Arena International published a new perspective from him on the importance of private stem cell treatment clinics to the future of stem cell biomedicine. The article considers that these clinics have been generally mischaracterized regarding their motivation and their research merit. Sherley emphasizes that their presently unregulated stem cell treatments are a part of the long tradition of routine medical practice also serving as a source of scientific discovery and medical innovation. The article makes recommendations for improvements in current treatment practices in private clinics that would increase the quality of care and the utility of knowledge obtained to accelerate progress in stem cell medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAsymmetrex Director Shares Vision for Company

Asymmetrex Founder’s Stem Cell Medicine Article Featured in CTA

by Asymmetrex on November 16, 2016

Advancing Stem Cell Medicine by Supplying Private Stem Cell Clinics

James Sherley, Asymmetrex, considers the potential benefits to stem cell medicine and stem cell science

Presently, in stem cell science and stem cell medicine, there exists a high degree of prejudice against private medical practices that offer stem cell treatments. When describing these private stem cell clinics, many reports written by disapproving stem cell scientists and stem cell medicine clinicians refer to the treating physicians as charlatans exploiting patients’ desperation and ignorance for money. Additionally, they’re regarded as unknowing pawns, themselves exploited by unsavory purveyors of poorly defined purported stem cell preparations. These reports warn that the supplied preparations may not only be ineffective, but they also may not contain any stem cells at all.

In contrast to this pejorative view held by well-known scientists and physicians in the field of stem cell biomedicine, many patients and patient advocate groups actively demand freedom for private stem cell clinics to operate without interference. The general sentiment being that regulatory agencies, like the US Food and Drug Administration (FDA) might restrict private clinics from exploring potentially beneficial novel stem cell treatments.

One factor responsible for this opposing view by patients is impatience with the generally slow, often protracted, and highly expensive regulatory path that new medical treatments must travel before receiving approval for general use. But there is also a fundamental distinction at play that could be seen as giving considerable credence to patients’ call for unregulated operation of private stem cell clinics. That distinction is the difference in the core principles that motivate stem cell medicine versus those that motivate stem cell science.

To read the rest of the article click here.

Clinical Trials Arena is an editorial website that provides content as an educational resource to help address the key challenges in the global clinical trial space.

Read More
AsymmetrexAsymmetrex Founder’s Stem Cell Medicine Article Featured in CTA

Asymmetrex and Zing Conferences Partner to Address Progress in Stem Cell Medicine

by Asymmetrex on October 25, 2016

Stem cell biotechnology start-up company Asymmetrex and not-for-profit scientific conference developer Zing Conferences have teamed up to provide a unique scientific forum for identifying and solving challenging problems that currently limit progress in stem cell biomedicine. Scheduled for February 18-21 in San Diego, California in the United States, the conference will feature invited presentations from prominent experts in the fields of stem cell biology and stem cell biomedicine and talks selected from abstracts for multidisciplinary research and clinical studies submitted by November 21.

Asymmetrex and Zing Conferences Partner to Address Progress in Stem Cell Medicine

At a recent pharmaceutical industry conference, the founder and director of biotech start-up Asymmetrex, James L. Sherley, asked a panel of noted investors, who were reviewing promising new pharmaceutical and biopharmaceutical companies for investment, “What are the stem cell medicine companies on your radar screen for investment?” Silence followed. The silence was a telling indicator of the state of progress in stem cell medicine.

Although there are many companies and institutions seeking to develop therapeutics based on stem cells, new effective stem cell therapies are yet to join the half century of success by hematopoietic stem cell transplantation therapy, which includes bone marrow, cord blood, and mobilized peripheral blood treatments. Instead, there is a growing mountain of failed efforts, which in many cases have occurred after significant hype.

Many important discoveries in stem cell biology have occurred in the last two decades, but, so far, they have not translated into effective new approved therapies. In more recent years, reports of stem cell treatments in private clinics have mushroomed, but the general applicability of these procedures is uncertain, at best; and possibly, they may not be reliable at all. In both cases, approved and unregulated, many basic barriers preclude faster progress in stem cell medicine. Examples of barriers include deficient biological knowledge, stem cell technical barriers, treatment logistics barriers, regulatory barriers, and financing barriers.

During nearly nine years of leading adult tissue stem cell bioengineering research as a professor at the Massachusetts Institute of Technology, Asymmetrex director Sherley’s focus was engineering solutions for difficult problems in stem cell biomedicine. Asymmetrex’s technologies that address the technical challenges of identifying, counting, and producing adult tissue stem cells reflect this bearing and expertise. Sherley believes that “success in solving tough problems in science and medicine begins with first recognizing problems and then facing the essentiality of solving them.”

In April 2015, Sherley was approached with an opportunity to share his focus on problem solving more widely with the field of stem cell medicine. Jane Hill, CEO of Zing Conferences invited him to organize a conference in the discipline of stem cell biomedicine. “Challenges, Solutions, and Progress in Stem Cell Medicine” is the product of that invitation.

Fifteen noted experts in diverse scientific, engineering, and medical disciplines relevant to stem cell medicine accepted invitations as featured speakers for the conference. Together, they will set the agenda for recognizing, facing, and discussing possible solutions for long-standing problems in stem cell biology and stem cell medicine. The preeminent hematopoietic stem cell physician scientist Peter Quesenberry, M.D. will intrigue conference goers with a keynote address emphasizing that even the paragon of stem cell transplantation medicine, bone marrow transplantation, still has unsolved problems that keep it from its full potential.

In addition to the invited presentations, many talks will be selected from submitted abstracts of attendees that detail important problems and solutions. These presentations are anticipated to resonate with the invited topics, as well as introduce new insights that may have not yet entered the broader consciousness of the field. The deadline for abstract submissions is November 21.

Unlike many scientific conference production companies that have emerged in the past twenty years, Zing Conferences recently became a not-for-profit. Proceeds from the conference organized with Asymmetrex will be used to support conference speaker travel needs, be applied to assist in increasing the demographic diversity of conference participants, and provide funds for biomedical research. In their partnership, both Asymmetrex and Zing Conferences achieve their goal of developing a unique scientific forum that will mingle investigators of diverse background and discipline towards an integration that may prove essential to achieving more rapid advances in stem cell medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

 

Read More
AsymmetrexAsymmetrex and Zing Conferences Partner to Address Progress in Stem Cell Medicine

CEOCFO Magazine Features Asymmetrex’s ‘Revolutionary New Technology’

by Asymmetrex on October 3, 2016

Asymmetrex Director James L. Sherley, M.D., Ph.D. had a one-on-one interview with the senior editor of CEOCFO Magazine about Asymmetrex and the AlphaSTEM Test. CEOCFO Magazine is a weekly publication that produces in-depth interviews with several top corporate executives.

The interview goes into detail about the science behind the AlphaSTEM Test and why counting stem cells is important and crucial to the progression of stem cell transplant therapies, drug development, and stem cell medicine.

CEOCFO: Dr. Sherley, the tagline on your Asymmetrex website is technologies for stem cell medicine. What are you working on now?  

Dr. Sherley: Our lead product that we are working on now, that has actually completed development and we are now marketing, is a new technology for counting adult tissue stem cells. Well call it the AlphaSTEM Test.

CEOCFO: Why do we need to count them? Would give us a little context?

Dr. Sherley: If you think about the way we have done drug development and drug use since the beginning of medicine, we do it by knowing the amount of the agent that we are giving to the patient. We know the dose. If you think about any medications that you currently take, you take a certain number of milligrams and that dose information is giving you the information about how many of those drug molecules you are getting…

To read the entire interview click here.

 

Read More
AsymmetrexCEOCFO Magazine Features Asymmetrex’s ‘Revolutionary New Technology’

AlphaSTEM Technology Highlighted as a 2016 New Product by Science

by Asymmetrex on September 28, 2016

Asymmetrex’s AlphaSTEM Test technology is featured in Science, the magazine, as a new product for 2016.

Science is one of the most widely read scientific journals in the world, publishing some of the best research and articles across sciences. Here is what Science said in the feature about the AlphaSTEM Test:

Since the beginnings of mammalian tissue stem cell biology, counting has been the bane of both basic research and clinical stem cell studies. Biomarkers, such as CD34 and CD133, do not identify tissue stem cells with sufficient specificity for counting them. Asymmetrex’s AlphaSTEM technology, developed with AlphaSTAR Corporation, provides precise determinations of the number…

To read the rest of the feature click here.

Read More
AsymmetrexAlphaSTEM Technology Highlighted as a 2016 New Product by Science

Asymmetrex Announces New Adult Tissue Stem Cell Counting Contract Service at BioPharm America 2016

by Asymmetrex on September 27, 2016

 

Recently at BioPharm America 2016 in Boston, September 13-15, biotech start-up company Asymmetrex announced its new AlphaSTEM Test contract service for counting adult tissue stem cells. In addition to applications for pharmaceutical drug evaluations, the company highlighted applications of the new service for stem cell medicine, gene and gene-editing therapeutics, and general stem cell biomedical research.

Asymmetrex Announces a New Adult Tissue Stem Cell Counting Contract Service to Pharmaceutical and Stem Cell Medical Companies at BioPharm America 2016 in Boston

Asymmetrex, LLC is a Boston-based start-up company whose three years of existence are benchmarked by yearly attendance to BioPharm America conferences in Boston. A signature feature of BioPharm conferences is pre-arranged one-on-one meetings primarily among pharma companies, pharma investors, and pharma suppliers. In addition, there are workshops for new companies to hone their business pitch skills, to gain knowledge of reigning and emerging industry trends, and to give presentations of their business vision and progress.

For the past three years, while developing the first technology able to count adult tissue stem cells, Asymmetrex Director James L. Sherley, M.D., Ph.D. has attended BioPharm America in Boston to update the company’s progress, increase its visibility, and extend its business network. In 2014, the company’s new AlphaSTEM Test technology was largely a concept that existed only as computer models of a new computational simulation method for counting adult tissue stem cells. In 2015, Sherley shared with conference participants experimental data to validate the company’s 2014 projections. In the 2016 conference, he announced that the company is now actively recruiting clients for a new adult tissue stem cell counting contract service.

Pharmaceutical companies are a major client group targeted for the new service. By counting tissue stem cells, drug candidates that are stem cell-toxic can be identified by the new AlphaSTEM Test service. Stem cell-toxic drugs cause chronic organ failure, which accounts for an estimated half of drug failures due to safety concerns. Currently, induction of chronic organ failure is detected by animal studies and clinical trials. Deployment of the AlphaSTEM Test service would identify such ill-fated drug candidates earlier and at a greatly reduced cost. Asymmetrex estimates that widespread adoption of its new contract service could save the U.S. pharmaceutical industry $4-5 billion each year.

A second major application for the new contract service is the determination of adult tissue stem cell dose. In current stem cell treatments, whether in unregulated private clinics, or in approved therapies like bone marrow stem cell and cord blood stem cell transplantation, or in FDA-approved clinical trials, the dose of the treating stem cells is unknown. Asymmetrex Director Sherley expressed to BioPharm America 2016 participants that the lack of stem cell dose data is an unmet need that is stifling progress in stem cell science and stem cell medicine. Sherley envisioned that, “By BioPharm America 2017, rapid adoption of Asymmetrex’s new tissue stem cell counting service could begin a revolution of change not only in how stem cell medicine is performed, but also in how it is regarded.” In a recent interview with Clinical Trials Arena, Sherley discussed the essential elements of this advance in anticipation of addressing an upcoming November Summit on Preclinical Development Operations in Boston.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAsymmetrex Announces New Adult Tissue Stem Cell Counting Contract Service at BioPharm America 2016

Asymmetrex is Featured in Clinical Trials Arena Article

by Asymmetrex on September 22, 2016

James Sherley, Director, Asymmetrex, talks to CTA to discuss a disruptive innovation that could change stem cell research

Previously in scientific research, there has been no way to count tissue stem cells, due to its difficulty. Experts over the years have lamented the lack of available technology, resigning themselves to not being able to resolve that problem.

But is that about to change?

James Sherley is the founder and director of Asymmetrex, an adult stem cell biotechnology start-up company. As the developer of AlphaSTEM Technology – a product that counts tissue stem cells – Sherley has been able to achieve a method that hasn’t been possible for 50 years.

In this compelling interview, Sherley sits down with CTA to explain how AlphaSTEM could mark a paradigmatic shift in stem cell and clinical research.

To read the rest of the article click here!

Read More
AsymmetrexAsymmetrex is Featured in Clinical Trials Arena Article